Azitra Inc (AZTR) AI Stock Analysis

• Market Cap: $2.54M
• Dividend Yield: N/A
• Average Volume (3M): 169.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: -100.00%
• EPS Growth: 93.82%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.67
• Shares Outstanding: 5,404,968
• 10 Day Avg. Volume: 152,326
• 30 Day Avg. Volume: 169,784
• PEG Ratio: <0.01
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.21
• P/FCF Ratio: -0.16
• Enterprise Value/Market Cap: 1.49
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -11.19
• Enterprise Value/Ebitda: -0.37
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $0.50 ▲(47.06% Upside)

Azitra Inc's overall stock score is primarily impacted by its financial performance, characterized by significant revenue growth but overshadowed by high losses and negative cash flows. Technical analysis indicates a bearish trend, and valuation metrics are unfavorable due to a negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.

Positive Factors

Revenue Growth

The substantial increase in revenue indicates successful product commercialization and market acceptance, supporting long-term growth potential.

Equity Position

A strong equity position enhances financial stability and provides a buffer against operational challenges, supporting future investment and growth.

Proprietary Technology

The proprietary technology platform offers a competitive edge in developing innovative therapies, potentially leading to sustained market leadership.

Negative Factors

High Losses

Ongoing high losses and negative cash flows indicate operational inefficiencies, which could hinder long-term financial sustainability and growth.

Negative Cash Flow

Negative cash flow limits the company's ability to fund operations and invest in growth without relying on external financing, posing long-term risks.

NYSE Compliance Issues

Noncompliance with NYSE listing requirements could lead to delisting, affecting investor confidence and access to capital markets.

Azitra Inc Business Overview & Revenue Model

Company Description

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

How the Company Makes Money

Azitra Inc generates revenue through a combination of product sales, licensing agreements, and collaborations with pharmaceutical companies. The primary revenue stream comes from the commercialization of its therapeutic products once they receive regulatory approval. In addition, Azitra may enter into partnerships with larger pharmaceutical companies for co-development and distribution of its products, which can provide upfront payments and milestone payments tied to clinical progress. The company also focuses on securing grants and funding for its research initiatives, which can supplement its income and support ongoing development efforts.

Azitra Inc Financial Statement Overview

Summary

Azitra Inc shows significant revenue growth, but persistent high losses and negative cash flows indicate operational inefficiencies and financial vulnerabilities. The balance sheet reflects improved equity, yet high liabilities and substantial cash burn remain critical challenges.

Income Statement

Azitra Inc reported significant revenue growth from $686,000 in 2023 to $7,500,000 in 2024, indicating a positive trajectory in revenue generation. However, the company suffers from extremely high net and operating losses, demonstrated by negative EBIT and EBITDA figures. The net profit margin remains negative due to substantial operational expenses surpassing revenue gains.

Balance Sheet

The balance sheet shows a strong equity position with stockholders' equity of $5,698,298,000 in 2024, reflecting a positive turnaround from negative equity in previous years. The debt-to-equity ratio is low, indicating prudent financial leverage. However, considerable liabilities could pose risks if revenue growth does not continue.

Cash Flow

Negative operating cash flows of -$10,183,740,000 in 2024 highlight cash constraints, limiting operational flexibility. Free cash flow remains deeply negative, though slight improvement is seen from the previous period. The lack of positive cash flows raises concerns about the company's ability to fund operations without external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	7.50M	686.00K	284.00K	110.00K
Gross Profit	-338.37K	7.50M	686.00K	284.00K	110.00K
EBITDA	-10.27M	-8.50M	-10.67M	-10.02M	-8.79M
Net Income	-11.11M	-8.97M	-11.28M	-10.68M	-8.94M
Balance Sheet
Total Assets	4.30M	7.36M	5.12M	7.17M	10.20M
Cash, Cash Equivalents and Short-Term Investments	1.40M	4.55M	1.80M	3.49M	8.04M
Total Debt	795.25K	555.51K	885.95K	7.73M	992.02K
Total Liabilities	2.02M	1.66M	2.20M	43.43M	35.97M
Stockholders Equity	2.28M	5.70M	2.91M	-36.26M	-25.77M
Cash Flow
Free Cash Flow	-11.10M	-10.56M	-7.68M	-8.69M	-8.72M
Operating Cash Flow	-10.92M	-10.18M	-7.36M	-8.35M	-8.07M
Investing Cash Flow	-214.58K	-379.25K	-318.26K	-336.76K	-652.27K
Financing Cash Flow	5.27M	13.32M	5.98M	4.13M	992.86K

Azitra Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTR, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.54, and below the 200-day MA of 1.40, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 38.61 is Neutral, neither overbought nor oversold. The STOCH value of 65.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTR.

Azitra Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INM	40 Underperform	$3.70M	-0.19	-82.17%	―	-3.27%	51.83%
AZTR	38 Underperform	$2.54M	-0.08	-215.04%	―	-100.00%	93.82%
ONCO	33 Underperform	$4.76M	>-0.01	-263.57%	―	-34.58%	96.41%
OGEN	29 Underperform	$4.66M	-0.04	-168.95%	―	―	90.27%
ENVB	24 Underperform	$2.95M	-0.04	-262.78%	―	―	79.45%

Azitra Inc Corporate Events

Azitra Inc Faces NYSE Compliance Deadline Notice

On October 1, 2025, Azitra, Inc. received a notice from NYSE American LLC regarding non-compliance with the minimum stockholders’ equity requirement, having only $2.2 million against the required $4 million. Azitra has until October 31, 2025, to submit a compliance plan to avoid delisting, with a deadline for achieving compliance by April 1, 2027. The notice does not immediately affect the company’s stock trading or operations.

The most recent analyst rating on (AZTR) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.

Azitra Inc.’s ATR-04 Study: A Potential Game-Changer for Rash Treatment

Azitra Inc. recently updated its clinical study titled A Phase 1b/2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of ATR-04 to Reduce the Severity of Epidermal Growth Factor Inhibitor Associated Papulopustular Rash. The study aims to assess the safety and tolerability of ATR-04, a topical ointment designed to alleviate facial rashes linked to epidermal growth factor receptor inhibitors. This research is significant as it addresses a common side effect of cancer treatments, potentially improving patient quality of life.

Azitra Inc.’s ATR04-484 Study: A Promising Step in Treating EGFRi-Associated Rash

Azitra Inc. is conducting a study titled ‘A Phase 1/2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety, Bioavailability, and Effect of Topically Administered ATR04-484 for Moderate to Severe EGFRi-Associated Dermal Toxicity.’ The study aims to assess the safety and efficacy of ATR04-484, a topical treatment for skin rashes in patients undergoing EGFR inhibitor therapy. This research is significant as it seeks to address common side effects of cancer treatments, potentially improving patient quality of life.

Azitra Inc Modifies Agreement with Alumni Capital

On August 26, 2025, Azitra, Inc. entered into a Modification Agreement with Alumni Capital LP to amend terms of a previous Purchase Agreement. This allows Azitra to sell up to $20 million of its common stock to Alumni Capital, with specific options for determining the purchase price. The agreement provides flexibility in stock sales, potentially impacting Azitra’s financial strategy and market operations.

The most recent analyst rating on (AZTR) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.

Azitra Inc Announces Reverse Stock Split Implementation

On August 20, 2025, Azitra, Inc. filed a certificate of amendment to implement a 1-for-6.66 reverse stock split of its common stock, following approval by its stockholders earlier in February 2025. This reverse stock split will take effect on August 21, 2025, and the company’s stock will begin trading on a split-adjusted basis on the NYSE American. The reverse stock split aims to consolidate every 6.66 shares into one, without affecting the par value or other terms of the common stock, and stockholders entitled to fractional shares will receive cash payments instead.

The most recent analyst rating on (AZTR) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.